Clinical development of phosphatidylinositol 3-kinase inhibitors for non-Hodgkin lymphoma

Xiaosheng Fang,Xin Wang,Xiangxiang Zhou

doi:10.1186/2050-7771-1-30

Abstract

Phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway is extensively explored in cancers. It functions as an important regulator of cell growth, survival and metabolism. Activation of this pathway also predicts poor prognosis in numerous human malignancies. Drugs targeting this signaling pathway have been developed and have shown preliminary clinical activity. Accumulating evidence has highlighted the important role of PI3K in non-Hodgkin lymphoma (NHL), especially in the disease initiation and progression. Therapeutic functions of PI3K inhibitors in NHL have been demonstrated both in vivo and in vitro. This review will summarize recent advances in the activation of PI3K signaling in different types of NHL and the applications of PI3K inhibitors in NHL treatment.

Highlights

The Phosphatidylinositol 3-kinase (PI3K)/Akt/Mammalian target of rapamycin (mTOR) pathway plays a critical role in regulating cancer cell growth, survival, motility and metabolism [1]
As PI3K/Akt/mTOR pathway plays a key role in the proliferation and survival of lymphoma cell, various inhibitors targeting this pathway have been studied in different types of non-Hodgkin lymphoma (NHL) (Table 1)
The results showed that CAL-101 promoted Chronic lymphocytic leukemia (CLL) cells apoptosis in a dose- and time-dependent pattern

Summary

Introduction

The PI3K/Akt/mTOR pathway plays a critical role in regulating cancer cell growth, survival, motility and metabolism [1]. As PI3K/Akt/mTOR pathway plays a key role in the proliferation and survival of lymphoma cell, various inhibitors targeting this pathway have been studied in different types of NHL (Table 1). NVP-BEZ235, a dual PI3K and mTOR inhibitor, was indicated to be effective in inhibiting FL cell proliferation [14].

Results

Conclusion